Review
English
F. Abufalgha
Department of Surgery Misurata Central Hospital
JMJ Vol.3 No.2 (September) 2004: 9-13
Abstract
Hepatic resection is considered the best option for the treatment of hepatocellular carcinoma (HCC), with good reported survival rates, and less morbidity and mortality rates due to advances in diagnostic modalities and surgical techniques. In cirrhotic patients with deteriorated liver function, liver transplantation represents the best treatment for HCC, but it is limited by shortage of donors. In spite of satisfactory results of the surgical treatment for HCC, still there are a high percentage of unresectable tumours and recurrence rates. The development of non-surgical treatment modalities such as transarterial and local ablative therapies provides an opportunity for the management of unresectable tumours. These options are also used as adjuvant in the treatment of patients with resectable and transplantable tumours, post operatively to reduce the risk of recurrence, and to treat post resection recurrence. In this review, we discuss these various treatment options, and the results of many series concerned with the treatment of HCC.
by shortage of donors. In spite of satisfactory results of the surgical treatment for HCC, still there are a high percentage of unresectable tumours and recurrence rates. The development of non-surgical treatment modalities such as transarterial and local ablative therapies provides an opportunity for the management of unresectable tumours. These options are also used as adjuvant in the treatment of patients with resectable and transplantable tumours, post operatively to reduce the risk of recurrence, and to treat post resection recurrence. In this review, we discuss these various treatment options, and the results of many series concerned with the treatment of HCC.
Hepatic resection is considered the best option for the treatment of hepatocellular carcinoma (HCC), with good reported survival rates, and less morbidity and mortality rates due to advances in diagnostic modalities and surgical techniques. In cirrhotic patients with deteriorated liver function, liver transplantation represents the best treatment for HCC, but it is limited by shortage of donors. In spite of satisfactory results of the surgical treatment for HCC, still there are a high percentage of unresectable tumours and recurrence rates. The development of non-surgical treatment modalities such as transarterial and local ablative therapies provides an opportunity for the management of unresectable tumours. These options are also used as adjuvant in the treatment of patients with resectable and transplantable tumours, post operatively to reduce the risk of recurrence, and to treat post resection recurrence. In this review, we discuss these various treatment options, and the results of many series concerned with the treatment of HCC.
Hepatic resection is considered the best option for the treatment of hepatocellular carcinoma (HCC), with good reported survival rates, and less morbidity and mortality rates due to advances in diagnostic modalities and surgical techniques. In cirrhotic patients with deteriorated liver function, liver transplantation represents the best treatment for HCC, but it is limited by shortage of donors. In spite of satisfactory results of the surgical treatment for HCC, still there are a high percentage of unresectable tumours and recurrence rates. The development of non-surgical treatment modalities such as transarterial and local ablative therapies provides an opportunity for the management of unresectable tumours. These options are also used as adjuvant in the treatment of patients with resectable and transplantable tumours, post operatively to reduce the risk of recurrence, and to treat post resection recurrence. In this review, we discuss these various treatment options, and the results of many series concerned with the treatment of HCC.
Keywords: Hepatocellular Carcinoma, transarterial therapy, local ablative therapy
Link/DOI: http://www.jmj.org.ly/modules.php?name=News&file=article&sid=1316